Can Hodgkin-like PTLD be treated with Rituximab and weaning of immunosuppression, or is Hodgkin-directed chemotherapy necessary for cure?

PTLD presenting as classic Hodgkin lymphoma is one of the most rare types of PTLD. As such, there are no clinical trials addressing this condition. Pediatric approaches to polymorphic PTLD, in general, include reduction of immunosuppression, rituximab monotherapy, or rituximab with "light" chemotherapy including rituximab and prednisone (CPR).

Pediatric approaches to late onset monomorphic PTLD with cytogenetic features of non-Hodgkin lymphoma [for example, Burkitt lymphoma with t(8;14)] are more challenging - treatments for Burkitt leukemia/lymphoma are effective in this situation but are associated with frequent grade 3-5 hematologic and infectious toxicities and were never intended for patients with underlying immunodeficiency.

In terms ...